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dicted combination therapy with ATX, LAS, and A2As. This suggests these medi-
cations may be used differently in clinical practice.
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OBJECTIVES: Bipolar disorder (BD) is associated with a high burden on healthcare
resources. A secondary objective of the Wide AmbispectiVE study of the clinical
management and burden of bipolar disorder (WAVE-bd) was to assess healthcare
resource utilization among BD patients. METHODS: Multinational, multicenter,
non-interventional, cohort study of patients diagnosed with BD-I/BD-II with 1
mood episode in the preceding 12 months (retrospective data collection) followed
by a minimum 9 months’ prospective follow-up. Study population was represen-
tative of BD populations from 8 European and 2 Latin American countries. Multi-
variate analyses determined factors associated with higher incidence of resource
use (number of visits per year), measured by parameter estimates (ParEst [95% CI])
0. RESULTS: Multivariate analyses included 2,896 patients. Factors associated
with a higher incidence of hospitalizations included: psychotic symptoms during
the study index episode (0.08 [0.02; 0.14]); a higher number of previous hospitaliza-
tions (0.04 [0.03; 0.04]); receiving anxiolytics during the study index episode (0.12
[0.06; 0.17]); enrolment in hospital settings (0.13 [0.03; 0.23]). The incidence of emer-
gency room visits was increased in patients with: rapid cycling (0.13 [0.06; 0.19]); a
history of suicide attempts (0.08 [0.02; 0.14]); a higher number of previous hospital-
izations (0.01 [0.01; 0.02]). The incidence of programmed psychiatrist visits was
increased in patients: with rapid cycling (0.90 [0.36; 1.44]); with a higher number of
previous hospitalizations (0.11 [0.06; 0.16]); enrolled in private practices (1.31 [0.07;
2.55]); receiving antipsychotics during study index event (0.81 [0.37; 1.25]). Overall,
clinical factors associated with higher incidence of resource use included: rapid
cycling (2.22 [0.84; 3.61]); co-morbidity of thyroid disease (2.21 [0.49; 3.92]); a higher
number of previous hospitalizations (0.25 [0.12; 0.38]); receiving antipsychotics dur-
ing the study index episode (1.63 [0.50; 2.76]). CONCLUSIONS: Several clinical fac-
tors are associated with higher resource utilization in BD patients. These factors
could aid in identification of high-risk patients.
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OBJECTIVES: Mortality among schizophrenia patients is higher than the general
population. Antipsychotics are the mainstay of schizophrenia treatment but have
been linked to life threatening adverse events. Therefore the objective of the study
was to systematically review available literature examining the risk of mortality
associated with antipsychotic use among schizophrenia patients.METHODS: Sys-
tematic review of English literature was conducted in MEDLINE, PubMed,
PsychInfo, EMBASE, Cochrane databases, and IPA from 1966 to October 2011 using
nine element eligibility criteria to identify studies examining the association be-
tween antipsychotic use and mortality. The primary inclusion criteria involved
diagnosis of schizophrenia, exposure to antipsychotics, at least one year follow up,
and ascertainment ofmortality. Findings from case-control, cohort, and controlled
trial studies were abstracted for evidence table preparation and possible
meta-analyses. RESULTS: Overall sixteen studies were included after employing
nine element eligibility criteria. The studies were heterogeneous in terms of study
designs; follow up period, and control of selection bias and confounding. Conse-
quently meta-analysis was not conducted. Nine out of sixteen studies concluded
increased risk of mortality among antipsychotic users compared to non-users.
Three out of four studies examining the antipsychotic polypharmacy found signif-
icant positive effect onmortality. One out of two studies examining the compliance
with antipsychotics found negative effect on mortality. One out of two studies
examining association of antipsychotic dosages found significant association with
increased mortality. One study ascertained stable association with antipsychotic
treatment intensity and increased cardiovascular mortality while other found no
significant association. The follow up period varied from 1 to 17 years. Prospective
studies controlled for lifestyle related factors while retrospective studies for some
comorbidities and co-medications. CONCLUSIONS: Literature review revealed that
antipsychotic use and antipsychotic polypharmacy increased the risk of mortality.
Well designed observational studies accounting for selection bias and confounding
are needed to establish the relationship.
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OBJECTIVES:To study factors associatedwith risk of dropout amongheroin addicts
enrolled in a community-based methadone maintenance treatment (MMT) clinic
in Solo, Central Java, Indonesia. METHODS: This was an ambi-directional cohort
study. The index date was patients’ first entry identified from medical records.
Patients enrolled from September 2009 were followed up until departure from the
clinic or otherwise censored in May 2011. Other data collected were methadone
doses, risk behaviour, and sociodemographic characteristics. Kaplan-Meier
method was used to estimate retention rate and Cox proportional hazard regres-
sions were used to determine factors associated with dropout from treatment.
RESULTS: Ninety-eight patients aged 31.6 years old on average contributed to
14,804 person-days of folllowup. The retention ratewas 24.2%after 21monthswith
median retention time of 78 days. The median and maximum dose were 43.1 mg
and 150 mg, respectively. Multivariate analysis showed that methadone dose be-
low 80 mg (HR2.4, p0.014, 95% CI1.2-4.8) and absence of family support
(HR5.0, p0.001, 95% CI2.4-10.6) were significantly associated with risk of drop-
out. HIV status, overdose history, criminal record, duration of addiction, distance
from clinic, marital status, and employment were not statistically significant pre-
dictors of dropout. CONCLUSIONS: Despite high prevalence of injecting drug users
(IDUs) in the area, low retention rate of the MMT clinic indicates that the commu-
nity-based programmight have been suboptimally utilised or else poorlymanaged.
Attaining maintenance phase at a minimum dose of 60 mg was insufficient to
ensure compliance. Health workers should maintain relationships with patients’
family to help support and monitor the treatment. Similar studies in hospital or
correctional institution settings and/or other areas are needed to confirm the find-
ings as well as economic analyses to anticipate waste of resources.
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OBJECTIVES: Depressive disorders affect 35 million US adults annually. A large
US health plan offers some members a “Refill and Save Program” (RSP), with dis-
counted copayments for desvenlafaxine (DSV) and extended-release venlafaxine
(VENXR) when refilled within 30 days after previous fill run-out. This study com-
pared adherence between RSP and non-RSP cohorts.METHODS: This retrospective
claims database study examined adult commercial members with 1 claim for
DSV or VENXR fromOctober 1, 2009 – March 31, 2010; the first claim date was index
date. Members with schizophrenia were excluded. Members were continuously
enrolled for 6 months pre-index and 9 months post-index. Proportion of days cov-
ered (PDC) on index antidepressant was modeled with ordinary least-squares re-
gression, controlling for index antidepressant, naïve antidepressant use, demo-
graphic and plan characteristics. Subset analysis was conducted on naïve and
continuing index antidepressant users and on subjects with no change in post-
index RSP exposure. RESULTS: The study population included 46,138 members
withmean age 4812 years and 75.3% female, divided between RSP (n28,925) and
non-RSP (n17,213): 21.4% were naïve to their index antidepressants. Mean PDC
was 69% in RSP, 65% in non-RSP (p0.001). Regression results showed PDC was 6.5
percentage points higher (p0.001) in the RSP versus non-RSP cohort. PDC in RSP
cohort was 8.2 percentage points higher (p0.001) among naïve index antidepres-
sant users, and 6.4 percentage points higher (p0.001) among continuing users.
Analyses on those with no change in post-index RSP exposure yielded similar
significant results but with smaller effect. CONCLUSIONS: The RSP cohort, versus
non-RSP, had higher index antidepressant PDC. These results suggest that copay-
ment discounts may have a positive impact on adherence to desvenlafaxine and
extended-release venlafaxine HCl.
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OBJECTIVES: Compare health care resource utilization (HCRU) and costs between
patients prescribed opioids versus those who were not during emergency depart-
ment (ED) or inpatient visits. METHODS: Patients with ED/inpatient visits were
selected from the MarketScan Commercial and Medicare Supplemental Database
linked with the Marketscan Hospital Discharge Database (1/12007–9/30/2009). Pa-
tients prescribed opioids in the ED/inpatient setting were assigned to the ‘Opioid
Patient (RxOP)’ cohort. The first prescription date was the index date. Among pa-
tients not prescribed opioids, the ‘Non-Opioid Patient (NoRxOP)’ cohort, a random
date between the first ED/inpatient admission and 30SEPT2009 served as the index
date. Additional inclusion criteria were: age older than 12 years at index date, and
12months of continuous enrollment before and after the index date. Patients with
opioid prescriptions during the pre-index period were excluded. Differences in
patients’ age, gender, geographic region, comorbidities, and HCRU during the pre-
index period were adjusted by 1:1 propensity score (PS) matching (PSM). RESULTS:
Overall, opioids were prescribed in 56% of patients in ED, and 71% in inpatient
setting. After excluding patients with pre-index opioid use (N163), among 27,599
eligible patients, 68% (RxOP: N18,819) were prescribed opioids, and 32% (NoRxOP:
N8,780) were not. The majority of patients (96%, N18,031) were prescribed im-
mediate-release opioids and 4% (N788) extended-release opioids (LAO use
slightly higher in ED versus inpatient, 6.5% versus 3.7%, p0.01). Among the 5099 PS
matched patients, adjusted results showed that RxOP patients had more inpatient
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